Article
Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study.
Blood - 20 Feb 2020
Soverini Simona, Bavaro Luana, De Benedittis Caterina, Martelli Margherita, Iurlo Alessandra, Orofino Nicola, Sica Simona, Sorà Federica, Lunghi Francesca, Ciceri Fabio, Galimberti Sara, Baratè Claudia, Bonifacio Massimiliano, Scaffidi Luigi, Castagnetti Fausto, Gugliotta Gabriele, Albano Francesco, Russo Rossi Antonella Vita, Stagno Fabio, di Raimondo Francesco, D'Adda Mariella, di Bona Eros, Abruzzese Elisabetta, Binotto Gianni, Sancetta Rosaria, Salvucci Marzia, Capodanno Isabella, Girasoli Mariella, Coluzzi Sabrina, Attolico Immacolata, Musolino Caterina, Calistri Elisabetta, Annunziata Mario, Bocchia Monica, Stella Stefania, Serra Anna, Errichiello Santa, Saglio Giuseppe, Pane Fabrizio, Vigneri Paolo, Mignone Flavio, Laginestra Maria Antonella, Pileri Stefano Aldo, Percesepe Antonio, Tenti Elena, Rosti Gianantonio, Baccarani Michele, Cavo Michele, Martinelli Giovanni
Abstract excerpt
In chronic myeloid leukemia (CML) patients, tyrosine kinase inhibitors (TKIs) may select for drug-resistant BCR-ABL1 kinase domain (KD) mutants. Although Sanger sequencing (SS) is considered the gold standard for BCR-ABL1 KD mutation screening, next-generation sequencing (NGS) has recently been assessed in retrospective studies. We conducted a prospective, multicenter study (NEXT-in-CML) to assess the frequency...
Read the complete abstract on PubMed